Genflow Biosciences Share Discussion Threads

[aberdeano] 09/5/2024 13:43

Understanding our genetic makeup doesn't just satisfy curiosity. It holds the promise of revolutionary medical treatments, a better understanding of diseases, and even insights into the aging process.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) focuses on a centenarian variant of the SIRT6 gene, which has shown promising preclinical results. The implications are monumental, not just for aging but also for age-related diseases.

As we continue to advance in genetic research, companies like GenFlow Biosciences are pushing the boundaries of what's possible in healthcare. Here's to a future where understanding our genes could unlock the secrets to longevity and healthier lives.

More information here: hxxps://loom.ly/NQrjPyw

#genes #longevity #healthspan #GENF

[moneymunch] 09/5/2024 13:32

Genflow Biosciences advances three major programs in fight against ageing diseases

Published: 10:00 09 May 2024








View
Genflow Biosciences PLC
LSE:GENF
OTCQB:GENFF

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CE Dr Eric Leire tells Proactive's Stephen Gunnion the company had a successful year in 2023, allowing it to expand its research and development pipeline.

Leire highlighted three main programs during an interview. The first focuses on MASH (Metabolic Dysfunction-Associated Steatohepatitis), soon progressing to clinical trials, indicating a strong move towards addressing liver diseases. The second program deals with Werner Syndrome, a progeria-related condition, where Genflow is innovating with synthetic organoids to mimic human organ function for better clinical trial predictions. The third program targets sarcopenia in collaboration with Revatis SA, aiming to combat muscle loss associated with ageing.

The company has also engaged with regulatory agencies in Europe and the US, receiving positive feedback on its approach, particularly with its MASH program. It is awaiting further feedback from the FDA to decide the trial's location.

In addition to a recent £715,000 fundraise, Genflow's financial strategy relies heavily on grants, with recent significant funding from the Wallonia Region in Belgium, which Leire believes positions it well to continue its work without heavy reliance on venture capital.

[moneymunch] 09/5/2024 07:11

Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,600 followers
13h

This past week, the XBI rose 7.8%, marking its strongest gain in 10 weeks. Tim Opler of Stifel Financial Corp. compares it to the start of the Q1 rally, suggesting this could be a rally year for biotech.

With Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s numerous recent grants and exciting treatment development, the company is poised to capitalize on the movement.

Read more here:

[cyberbub] 08/5/2024 14:28

I can only sell 400k at the moment. I'm hoping the mid-morning unsuspension means that some people have missed it...

[moneymunch] 08/5/2024 14:09

Get UP there!!! Gla :-)

[moneymunch] 08/5/2024 10:54

8 May 2024



Genflow Biosciences Plc



Restoration of Listing



Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce that, following publication of the audited financial statements for the year ended 31 December 2023 (FY23 Results) on 7 May 2024, and having completed the upload of the FY23 Results to the Financial Conduct Authority's National Storage Mechanism at www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism, it has been advised by the FCA that the temporary suspension of listing of the Company's ordinary shares on the Official List of the Financial Conduct Authority is expected to be lifted later today, 8 May 2024, and that the listing on the Main Market of the London Stock Exchange, of the ordinary shares, will be restored.

[moneymunch] 08/5/2024 07:42

We're in the party steg, We're holding the Golden tickets, just imagine the demand if a Major JV partner is in the house!!! Gla holders....Excitement building in anticipation. :-)))

[steg] 08/5/2024 07:35

As long as we get to join the party 😂😂😂

[northeast14] 08/5/2024 07:23

Beginning to wonder if the re listing is being stalled for 3 parties to continue talks with Genflow. Just a theory

[moneymunch] 07/5/2024 20:39

I wonder who the other interested parties are??? :>]

"unedited text of its final results for the year ended 31 December 2023, announced earlier today, to assist shareholders and other interested parties."

[moneymunch] 07/5/2024 19:41

Given how hot the liver space is and how compelling Sirt6's importance and influence appears to be in multiple disease targets, then the following deal announced end of April, would be much more likely in the not too distant....although tomorrow would be fine with me. Gla :-)))



German pharma group Boehringer Ingelheim has struck an up to $1bn partnership with a UK biotech to develop treatments for chronic liver disease that aim to harness the organ’s capacity to regenerate.

Under the drug discovery partnership, Ochre Bio will receive $35mn in upfront and near-term payments, rising to more than $1bn in payments and royalties if treatments are successfully brought through clinical trials. It is a similar milestone-based structure to many partnerships in the pharmaceutical industry.


The liver is the only organ that can regrow and repair itself and Ochre Bio will seek to develop drugs that restore this ability in diseased livers.

The company’s work to date has involved analysing thousands of donated human livers to develop an understanding of the causes of disease, and studying whether making changes to RNA — a vital molecule for translating genetic information into proteins — can extend the lifespan of transplanted livers.

“What we’re trying to do is give the liver a little nudge in the right direction to support it to regenerate,” said Quin Wills, chief scientific officer and co-founder of Ochre Bio. “What happens in a cirrhotic liver is [cells] don’t have that decision-making process any more to start dividing and restoring capacity. By changing certain ‘switches̵7;, using these RNA therapies, we help them make those decisions again.”

[northeast14] 07/5/2024 19:30

Buyout for £500m……. Was a great dream I had last night

[steg] 07/5/2024 19:16

Won’t happen Eric’s a clever guy and knows what he as, not saying they wouldn’t sell just Nash and keep the rest but not at that valuation IMVHO. I would think just for a collaboration deal on Mash would see an up front in that kind of range and certainly not for the whole company, mind you stranger things have happened and I have learned to assume nothing in this life 😂👍

[marmiesz] 07/5/2024 18:48

I only hope it's not a take over approach. To be taken out at £15-20M would be a real shame as 12 months from now GENF will be on the cusp of some very exciting trials.Marmie

[moneymunch] 07/5/2024 16:38

I guess we'll find out tomorrow if any big news is up Eric's sleeve. The accounts were only 4 working days late, and so intriguing Eric decided to suspend shares on the 1st May, rather than simply annouce they would be one week late because of audit delays, unforeseen circumstances beyond their control, unrelated to cash flow and/or economic position.

The first payment of €777,000 from the 2.89m Euros grant is due to be received imminently, and so an RNS confirming this will be very well received, but still hoping for something even bigger and the reason for the ongoing suspension, despite the release of the accounts, whereby it stops those in the know and their mates from buying in before the event. Just a thought, but any major player/investor would certainly prefer it that way I reckon. Anyways, regardless of what may come, Genflow’s prospects and potential are looking very nice and I for one will be holding and adding for great things to come. Gla :-)

[moneymunch] 07/5/2024 15:43

Genflow Biosciences Plc, a biotechnology company focusing on longevity research and age-related diseases, has released its final results for the year ending 31 December 2023. The company has received significant non-dilutive research grants from the Government of Wallonia in Belgium, completed a successful fundraise, and made strategic progress with its key research programs in MASH and Werner Syndrome. These achievements, alongside the expansion of their intellectual property portfolio and collaborations with other biotech firms, highlight Genflow’s commitment to advancing its research pipeline and financial stability.

[tim000] 07/5/2024 14:42

Yes, it’s odd that the shares are still suspended and does suggest that further news is imminent.

[bri15] 07/5/2024 14:26

It's on LSE now,the results that is, normally when shares suspended they come straight back when results are sorted, maybe big news coming when restoration of trading RNS arrives.

[moneymunch] 07/5/2024 13:09

No problem, makes good reading, nothing we didn't already know, but certainly highlights the potential and prospects going forward, and so everything firmly crossed for more news from Eric to go with the re-listing. Gl :-)

[tim000] 07/5/2024 12:39

Thanks, I had failed to find it.

[moneymunch] 07/5/2024 12:29

I found it on my mobile courtesy of Mumblegrumble on LSE...go to home page and scroll down to the bottom whereby you can click on investors and shareholder documents thereafter. Gl :-)

[molatovkid] 07/5/2024 12:09

IR said it hadn't uploaded correctly.

[moneymunch] 07/5/2024 10:59

Cheers Steg, I'm out and about today and I can't seem to access it on my mobile. Fingers crossed Eric has got some big news to go along with confirmation of the suspension being lifted. Gl holders...Excitement building!!! ;-)

[steg] 07/5/2024 10:02

The financial report is on the website under investors section and shareholders documents 👍

[moneymunch] 07/5/2024 08:00

At least we know the Results are in, maybe their website designer/admin has slept in this morning??? Gla ;-)